Amgen’s Repatha Posts $1.085 Billion in Third-Quarter Sales
Sales rose 37% year over year, driven by volume growth, the company said.
Amgen's cholesterol drug Repatha hit $1.085 billion in third-quarter sales, a 37% increase from the same period a year ago. Volume growth drove the gains, the company said. The cardiovascular medicine is also generating new clinical data supporting its use. A pre-specified analysis of the Phase thr…